AU Patent

AU2025204821A1 — Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant

Assigned to Novo Nordisk AS · Expires 2025-08-14 · 1y expired

What this patent protects

#$%^&*AU2025204821A120250814.pdf##### Abstract The invention relates to pharmaceutical compositions comprising a peptide, such a GLP-1 peptide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such co…

USPTO Abstract

#$%^&*AU2025204821A120250814.pdf##### Abstract The invention relates to pharmaceutical compositions comprising a peptide, such a GLP-1 peptide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine. Abstract The invention relates to pharmaceutical compositions comprising a peptide, such a GLP-1 peptide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

Drugs covered by this patent

Patent Metadata

Patent number
AU2025204821A1
Jurisdiction
AU
Classification
—
Expires
2025-08-14
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.